<p><strong>Tilray Brands</strong> (NASDAQ: TLRY) 的股票在周四交易中下跌，因为该公司正在与德国的几家制药实体宣布战略合作伙伴关系。</p>
<p>Tilray 的合作伙伴关系涉及与 Tilray Medical、CC Pharma 和 14U Pharma 的合作，旨在增强他们在德国的市场存在。</p>
<p>自 2026 年 4 月 1 日起，该联盟将允许这些公司提供更广泛的产品，并改善药房的获取，利用 CC Pharma 已建立的分销网络，该网络支持全国超过 16,000 家药房。</p>
<p>这一战略举措旨在满足 B2B 药房需求和 B2C 患者需求，为合作药房提供处方药、折扣药品和 Tilray 的医疗大麻产品组合。</p>
<p>此次合作预计将加强 Tilray 在德国医疗市场的地位，该市场被认为是欧洲最具活力的市场之一。</p>
<p>整体市场正在经历轻微下跌，标准普尔 500 指数下跌 0.9%，材料行业小幅上涨 0.1%。尽管该行业表现积极，Tilray 的股票表现不佳，表明可能存在公司特定因素的影响。</p>
<h2>最近动态</h2>
<p>周三，该公司 推出了其新的 美国风格的轻啤酒 <strong>Pub Light</strong>，旨在扩展其饮料产品组合。</p>
<p>该发展紧随公司收购 <strong>BrewDog Brewing Australia Pty Ltd.</strong>，包括其布里斯班酿酒厂和 全国多个 BrewDog 酒吧地点。</p>
<h2>技术分析</h2>
<p>该股票目前交易价格比其 20 日简单移动平均线 (SMA) 低 5.2%，比其 50 日 SMA 低 12.9%，反映出看跌趋势。在过去 12 个月中，股票上涨了 11.79%。</p>
<p>相对强弱指数 (RSI) 为 40.00，属于中性区域，表明该股票既不超买也不超卖。</p>
<p>与此同时，MACD 显示值为-0.2730，信号线为-0.2795，表明由于 MACD 高于信号线，出现了看涨交叉。</p>
<p>中性 RSI 和看涨 MACD 的组合表明动能混合，表明交易者应关注股票方向的潜在变化。</p>
<ul>
<li><strong>关键阻力位</strong>：$8.00</li>
<li><strong>关键支撑位</strong>：$7.00</li>
</ul>
<p>Tilray 目前表现不及其行业，材料行业今天上涨 0.12%。</p>
<p>Tilray 与 CC Pharma 等公司的合作具有重要意义，因为它强化了 Tilray 在德国扩展其医疗平台的承诺。通过利用其已建立的分销网络，该公司旨在增强其市场存在并改善其产品的获取。</p>
<h2>财报与分析师展望</h2>
<p>Tilray Brands, Inc.普通股预计将在 2026 年 4 月 7 日（预计）提供下一个财务更新。</p>
<ul>
<li><strong>每股收益预估</strong>：亏损 1 美分</li>
<li><strong>收入预估</strong>：2.0315 亿美元（高于 1.8578 亿美元）</li>
</ul>
<p><strong>分析师共识与近期行动：</strong> 该股票持有持有评级。近期分析师的行动包括：</p>
<ul>
<li><strong>Roth Capital</strong>：中性（将目标价下调至$10.00）（1 月 20 日）</li>
</ul>
<h2>顶级 ETF 曝光</h2>
<ul>
<li><strong>Amplify Alternative Harvest ETF</strong> (NYSE: MJ)：12.38% 权重</li>
</ul>
<p><strong>重要性：</strong> 由于 TLRY 在这些基金中占有重要权重，任何显著的资金流入或流出都可能迫使自动买入或卖出该股票。</p>
<p><strong>TLRY 股票价格活动：</strong> 根据 Benzinga Pro 数据，Tilray Brands 的股票在周四发布时下跌 1.11%，报$7.14。</p>
<p><em>图片来源于 Shutterstock</em></p>

TLRY

<p>Tilray Brands（纳斯达克代码：TLRY）宣布与 CC Pharma 和 14U Pharma 建立战略合作伙伴关系，以增强其在德国的市场存在，合作自 2026 年 4 月 1 日起生效。尽管这一扩展，Tilray 的股价仍下跌 1.11%，至 7.14 美元，原因是整体市场疲软。此次合作旨在改善药房的可及性，并满足 B2B 和 B2C 的需求，利用 CC Pharma 的分销网络。分析师对该股票维持持有评级，预计每股收益将出现 1 美分的亏损，收入预计将上升至 2.0315 亿美元。Tilray 的股票目前表现不及其行业，反映出技术分析中的动能不一</p>

<p><strong>Tilray Brands</strong> (NASDAQ: TLRY) shares are trading lower on Thursday as the company is announcing a strategic partnership with several pharmaceutical entities in Germany.</p>
<div class="lb-trans"><p><strong>Tilray Brands</strong> (NASDAQ: TLRY) 的股票在周四交易中下跌，因为该公司正在与德国的几家制药实体宣布战略合作伙伴关系。</p>
</div><p>Tilray’s partnership involves collaboration with Tilray Medical, CC Pharma, and 14U Pharma, aimed at enhancing their market presence in Germany.</p>
<div class="lb-trans"><p>Tilray 的合作伙伴关系涉及与 Tilray Medical、CC Pharma 和 14U Pharma 的合作，旨在增强他们在德国的市场存在。</p>
</div><p>Effective April 1, 2026, this alliance will allow the companies to offer a broader range of products and improve pharmacy access, leveraging CC Pharma’s established distribution network, which supports over 16,000 pharmacies across the country.</p>
<div class="lb-trans"><p>自 2026 年 4 月 1 日起，该联盟将允许这些公司提供更广泛的产品，并改善药房的获取，利用 CC Pharma 已建立的分销网络，该网络支持全国超过 16,000 家药房。</p>
</div><p>This strategic move is designed to address both B2B pharmacy requirements and B2C patient needs, providing partner pharmacies with access to prescription medications, discounted medicines, and Tilray’s medical cannabis portfolio.</p>
<div class="lb-trans"><p>这一战略举措旨在满足 B2B 药房需求和 B2C 患者需求，为合作药房提供处方药、折扣药品和 Tilray 的医疗大麻产品组合。</p>
</div><p>The collaboration is expected to strengthen Tilray’s position in the German healthcare market, which is considered one of the most dynamic in Europe.</p>
<div class="lb-trans"><p>此次合作预计将加强 Tilray 在德国医疗市场的地位，该市场被认为是欧洲最具活力的市场之一。</p>
</div><p>The broader market is experiencing a slight downturn, with the S&amp;P 500 down 0.9% and the Materials sector gaining a modest 0.1%. Despite the positive sector performance, Tilray’s stock is underperforming, indicating that company-specific factors may be at play.</p>
<div class="lb-trans"><p>整体市场正在经历轻微下跌，标准普尔 500 指数下跌 0.9%，材料行业小幅上涨 0.1%。尽管该行业表现积极，Tilray 的股票表现不佳，表明可能存在公司特定因素的影响。</p>
</div><h2>Recent Developments</h2>
<div class="lb-trans"><h2>最近动态</h2>
</div><p>On Wednesday, the company launched its new American-style light beer, <strong>Pub Light</strong>, aimed at expanding its beverage portfolio.</p>
<div class="lb-trans"><p>周三，该公司 推出了其新的 美国风格的轻啤酒 <strong>Pub Light</strong>，旨在扩展其饮料产品组合。</p>
</div><p>The development follows the company's acquisition of <strong>BrewDog Brewing Australia Pty Ltd.</strong>, including its Brisbane brewery and several BrewDog bar locations across the country.</p>
<div class="lb-trans"><p>该发展紧随公司收购 <strong>BrewDog Brewing Australia Pty Ltd.</strong>，包括其布里斯班酿酒厂和 全国多个 BrewDog 酒吧地点。</p>
</div><h2>Technical Analysis</h2>
<div class="lb-trans"><h2>技术分析</h2>
</div><p>The stock is currently trading 5.2% below its 20-day simple moving average (SMA) and 12.9% below its 50-day SMA, reflecting a bearish trend. Over the past 12 months, shares have increased by 11.79%.</p>
<div class="lb-trans"><p>该股票目前交易价格比其 20 日简单移动平均线 (SMA) 低 5.2%，比其 50 日 SMA 低 12.9%，反映出看跌趋势。在过去 12 个月中，股票上涨了 11.79%。</p>
</div><p>The RSI is at 40.00, which is considered neutral territory, indicating that the stock is neither overbought nor oversold.</p>
<div class="lb-trans"><p>相对强弱指数 (RSI) 为 40.00，属于中性区域，表明该股票既不超买也不超卖。</p>
</div><p>Meanwhile, the MACD shows a value of -0.2730, with the signal line at -0.2795, suggesting a bullish crossover as the MACD is above the signal line.</p>
<div class="lb-trans"><p>与此同时，MACD 显示值为-0.2730，信号线为-0.2795，表明由于 MACD 高于信号线，出现了看涨交叉。</p>
</div><p>The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that traders should watch for potential changes in the stock’s direction.</p>
<div class="lb-trans"><p>中性 RSI 和看涨 MACD 的组合表明动能混合，表明交易者应关注股票方向的潜在变化。</p>
</div><ul>
<li><strong>Key Resistance</strong>: $8.00</li>
<li><strong>Key Support</strong>: $7.00</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>关键阻力位</strong>：$8.00</li>
<li><strong>关键支撑位</strong>：$7.00</li>
</ul>
</div><p>Tilray is currently underperforming its sector, with the Materials sector gaining 0.12% today.</p>
<div class="lb-trans"><p>Tilray 目前表现不及其行业，材料行业今天上涨 0.12%。</p>
</div><p>Tilray’s partnership with CC Pharma and others is significant as it reinforces Tilray’s commitment to expanding its healthcare platform in Germany. By leveraging its established distribution networks, the company aims to enhance its market presence and improve access to its products.</p>
<div class="lb-trans"><p>Tilray 与 CC Pharma 等公司的合作具有重要意义，因为它强化了 Tilray 在德国扩展其医疗平台的承诺。通过利用其已建立的分销网络，该公司旨在增强其市场存在并改善其产品的获取。</p>
</div><h2>Earnings &amp; Analyst Outlook</h2>
<div class="lb-trans"><h2>财报与分析师展望</h2>
</div><p>Tilray Brands, Inc. Common Stock is slated to provide its next financial update on April 7, 2026 (estimated).</p>
<div class="lb-trans"><p>Tilray Brands, Inc.普通股预计将在 2026 年 4 月 7 日（预计）提供下一个财务更新。</p>
</div><ul>
<li><strong>EPS Estimate</strong>: Loss of 1 cent</li>
<li><strong>Revenue Estimate</strong>: $203.15 million (Up from $185.78 million)</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>每股收益预估</strong>：亏损 1 美分</li>
<li><strong>收入预估</strong>：2.0315 亿美元（高于 1.8578 亿美元）</li>
</ul>
</div><p><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Hold Rating. Recent analyst moves include:</p>
<div class="lb-trans"><p><strong>分析师共识与近期行动：</strong> 该股票持有持有评级。近期分析师的行动包括：</p>
</div><ul>
<li><strong>Roth Capital</strong>: Neutral (Lowers Target to $10.00) (Jan. 20)</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Roth Capital</strong>：中性（将目标价下调至$10.00）（1 月 20 日）</li>
</ul>
</div><h2>Top ETF Exposure</h2>
<div class="lb-trans"><h2>顶级 ETF 曝光</h2>
</div><ul>
<li><strong>Amplify Alternative Harvest ETF</strong> (NYSE: MJ): 12.38% Weight</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Amplify Alternative Harvest ETF</strong> (NYSE: MJ)：12.38% 权重</li>
</ul>
</div><p><strong>Significance:</strong> Because TLRY carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.</p>
<div class="lb-trans"><p><strong>重要性：</strong> 由于 TLRY 在这些基金中占有重要权重，任何显著的资金流入或流出都可能迫使自动买入或卖出该股票。</p>
</div><p><strong>TLRY Stock Price Activity:</strong> Tilray Brands shares were down 1.11% at $7.14 at the time of publication on Thursday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>TLRY 股票价格活动：</strong> 根据 Benzinga Pro 数据，Tilray Brands 的股票在周四发布时下跌 1.11%，报$7.14。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

Tilray 通过战略制药协议扩大在德国的医疗保健业务